This marks the completion of the intended refinancing program for our bridge facility at an overall blended interest rate across the various components of the refinancing that is highly satisfactory, which we believe supports our intention to maintain our well-established dividend policy and investment grade credit rating. In addition, Takedas vaccine business will continue to address the worlds most pressing public health needs. Please note that the Acquisition remains subject to certain conditions, including approval by the shareholders of both companies. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. The combined group will build on existing partnerships, including Takedas more than 180 active partnerships with academia, biotechnology companies and startups, to further enrich the pipeline. Upon the closing of the transaction, Takeda shareholders will own approximately 50 percent of the combined group. It is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the Acquisition or otherwise nor will there be any sale, issuance, exchange or transfer of securities of Shire or Takeda pursuant to the Acquisition or otherwise in any jurisdiction in contravention of applicable law.Forward Looking StatementsThis Announcement contains certain statements about Takeda and Shire that are or may be forward looking statements, including with respect to a possible combination involving Takeda and Shire. Takeda will host an additional audio webcast at 10.00 p.m. JST / 2.00 p.m. BST / 9.00 a.m. Such risks and uncertainties include, but are not limited to, the possibility that a possible combination will not be pursued or consummated, failure to obtain necessary regulatory approvals or to satisfy any of the other conditions to the possible combination if it is pursued, adverse effects on the market price of Takedas ordinary shares and on Takedas or Shires operating results because of a failure to complete the possible combination, failure to realise the expected benefits of the possible combination, negative effects relating to the announcement of the possible combination or any further announcements relating to the possible combination or the consummation of the possible combination on the market price of Takedas or Shires ordinary shares, significant transaction costs and/or unknown liabilities, general economic and business conditions that affect the combined companies following the consummation of the possible combination, changes in global, political, economic, business, competitive, market and regulatory forces, future exchange and interest rates, changes in tax laws, regulations, rates and policies, future business combinations or disposals and competitive developments. Nomination Committee and Compensation Committee, Audit and Supervisory Committee and Internal Audit, We will become a global, values-based, R&D-driven, biopharmaceutical leader, Supplier Registration Process via Ariba Commerce Cloud. The substantial cash flow generation expected to result from the Acquisition will enable the combined group to de-lever quickly following completion. The company is confident that it will retain its investment grade credit rating and return to a net debt to EBITDA ratio of 2.0x or less within three to five years following completion.Weber will present at the J.P. Morgan Healthcare Conference at 3:30 p.m. PST on January 8, 2019.Notice regarding the Acquisition of the Entire Issued and To Be Issued Share of Shire plc. An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Takeda acquisition of Shire : Japanese pharma company Takeda Pharmaceutical wrapped up its previously announced acquisition of Shire, an Irish biotech company with a focus on rare diseases, for $62 billion, as per the latest pharma acquisition news. The Acquisition is also expected to be earnings accretive per Takeda share on a reported basis within three years post completion. Takeda Pharmaceutical Company Limited (TSE: 4502) (Takeda) and Shire plc (LON: SHP) (Shire) today announced that they have reached agreement on the terms of a recommended offer pursuant to which Takeda will acquire the entire issued and to be issued ordinary share capital of Shire. Copyright 1995-2022 Takeda Pharmaceutical Company Limited. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. We are also maintaining our existing dividend policy and updating our capital allocation policy to allow for share buybacks in the future when appropriate. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs, including the ones under development.Publication on WebsiteIn accordance with Rule 26.1 of the Code, a copy of this Announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on November 13, 2018. Takeda is committed to addressing the worlds biggest challenges to sustainable development over the long term. This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takedas future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. The Acquisition is expected to result in Takeda being the only pharmaceutical company listed on both the Tokyo Stock Exchange in Japan, where it will continue to have its primary listing, and the New York Stock Exchange in the U.S., enabling it to access two of the worlds largest capital markets. Takeda expects recurring pre-tax cost synergies for the combined group to reach a run-rate of at least $1.4 billion per annum by the end of the third fiscal year following completion of the acquisition. Related reports can be found in the Rule 2.7 Announcement made by Takeda on May 8, 2018, as well as information regarding the method of calculation of the synergies and the costs to achieve such synergies.Shire Scheme Document and Shareholder MeetingsTakeda also notes that Shire has today published its scheme document (the Scheme Document) in relation to the Acquisition and plans to hold its shareholder meetings in connection with the Acquisition on December 5, 2018, following Takedas EGM.The Scheme Document and certain other documents relating to the Acquisition will shortly be available to view on the Company's website at www.takeda.com/investors/offer-for-shire.Notice of the Resolution of the Date and Agenda of the Extraordinary General Meeting of Shareholders. 01.09.2019 Takeda CEO Optimistic About Growth Prospects as Drugmaker Finalizes Shire Takeover Source: FirstWord Takeda announced that it has completed its $62-billion acquisition of Shire. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. No shares or other securities are being offered to the public by means of this press release. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. The substantial cash flow generation expected to result from the acquisition will enable the combined group to de-lever quickly following completion. It is currently contemplated that, prior to completion, the commitments under the bridge facility agreement will be reduced or refinanced with a combination of long-term debt, hybrid capital and available cash resources. Takedas experienced management team has a proven track record of executing complex business integrations and large-scale transformations, and is well-positioned to successfully integrate Shire and maximize the value of the combination. Takeda is committed to addressing the worlds biggest challenges to sustainable development over the long term. Takeda finally cracked the deal after four . Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this Announcement. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. Except to the extent otherwise required by applicable law, neither Takeda nor Shire undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.No profit forecasts or estimatesUnless expressly stated otherwise, nothing in this Announcement (including any statement of estimated synergies) is intended as a profit forecast or estimate for any period and no statement in this Announcement should be interpreted to mean that earnings or earnings per share or dividend per share for Takeda or Shire, as appropriate, for the current or future financial years would necessarily match or exceed the historical published earnings or earnings per share or dividend per share for Takeda or Shire, as appropriate.Medical informationThis Announcement contains information about products that may not be available and in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Enhances Takedas cash flow profile, with management committed to delivering substantial annual cost synergies and generating attractive returns for shareholders. All together, Takeda will pay 46. OSAKA, Japan, October 28, 2021--Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) ("Takeda") announced that its Board of Directors resolved today to engage in the acquisition of its own . The merge has created a a global, value-based, R&D-driven biopharmaceutical leader headquartered in Japan, making the 237-year-old drug company one of the world's ten biggest pharmaceutical companies. In addition, Takeda will apply for its ADSs (each representing 0.5 Takeda shares) to be listed on the NYSE effective on or shortly after the effective date. OSAKA, Japan--(BUSINESS WIRE)-- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTIONTakeda Pharmaceutical Company Limited (the "Company or "Takeda") announces that it has today, December 3, 2018 (London time), entered into a Loan Agreement with . SHPG announced that its acquisition by Japan-based Takeda Pharmaceuticals for $62 billion has been approved by its shareholders. To help accelerate the de-leveraging process and ensure an optimal business mix, Takeda will consider selected disposals of non-core assets. Without limitation, forward looking statements often include words such as targets, plans, believes, hopes, continues, expects, aims, intends, will, may, should, would, could, anticipates, estimates, projects or words or terms of similar substance or the negative thereof. Guided by our values and our commitment to Patients, People and Planet, we will allocate capital to maximize value for patients and shareholders. Takeda's strengthened, highly innovative R&D engine enables the company to have a more global, robust and modality-diverse pipeline as well as to focus on breakthrough innovation.The combined annual revenue of the company, exceeding $30 billion USD, is mainly derived from the key business areas of Oncology, GI, Neuroscience, Rare Diseases and PDT.We are delighted that the acquisition was approved by an overwhelming majority of our shareholders at Takeda's extraordinary general meeting on December 5th, 2018. Takeda announced acquisition of Shire Plca rare drug specialist and a long-time rivalon May 8, 2018marking the largest bet of the year. All rights reserved. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Together, the combined group will have leading positions in two of the largest drug markets globally: the U.S. and Japan. We appreciate the support of our employees, partners and shareholders throughout the process. A presentation for the call will be available at: https://www.takeda.com/investors/reports/quarterly-announcements/quarterly-announcements-2018/. We are focusing on developing highly innovative medicines that contribute to making a difference in peoples lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Two centuries. Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and Shire plc (LON: SHP) ("Shire") today announced that they have reached agreement on the terms of a recommended offer pursuant to which Takeda will acquire the entire issued and to be issued ordinary share capital of Shire. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this Announcement.Additional risk factors that may affect future results are contained in Shires most recent Annual Report on Form 10-K and in Shires subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in ITEM1A: Risk Factors, and in Shires subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement. Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. The abstracts span Takeda's extensive hematology portfolio and research and development (R&D) pipeline, featuring data on multiple products and investigational candidates, supporting Takeda's commitment to helping healthcare professionals improve the way they treat patients as well as delivering innovative solutions for the . In addition, Shires portfolio will benefit from Takedas strong international presence in emerging markets and Japan. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Shire has strong expertise in rare diseases, an attractive modality-diverse mid- and late-stage pipeline, enriched with large-molecule programs, as well as cutting-edge technologies in gene therapy and recombinant proteins. That deal still needs shareholder and regulatory approvals. All statements other than statements of historical facts included in this Announcement may be forward looking statements. The JBIC Loan will finance a portion of the funds necessary for the acquisition of Shire plc (Shire) (the Acquisition) and reduce commitments under the 364-Day Bridge Credit Agreement entered into in connection with the Acquisition on May 8, 2018 (as amended on June 8, 2018 and October 26, 2018) (the Bridge Credit Agreement).We are pleased to have secured this loan from JBIC, an organization which promotes the maintenance and strengthening of the international competitiveness of Japanese industries, said Costa Saroukos, Chief Financial Officer of Takeda. With this combination, Shire helps create an even stronger biopharmaceutical company, with a robust R&D pipeline and expanded global footprint. Nomination Committee and Compensation Committee, Audit and Supervisory Committee and Internal Audit, We will become a global, values-based, R&D-driven, biopharmaceutical leader, Supplier Registration Process via Ariba Commerce Cloud. Shires highly complementary product portfolio and pipeline, as well as experienced employees, will accelerate our transformation for a stronger Takeda. Creates a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, with an attractive geographic footprint and provides the scale to drive future development. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. The acquisition will accelerate Takedas strategic transformation toward Vision 2025, and strong combined cash flows will enable continued investment in R&D. December 3, 2018: Takeda Announces Execution of Loan Agreement in Connection with Proposed Acquisition of Shire plc Shire Scheme Document, Shareholders Meetings and Settlement / November 12, 2018 - Shire Scheme Document November 12, 2018 - Shire General Meeting Form of Proxy